This is an HTML version of an attachment to the Freedom of Information request 'EFPIA and DG Trade'.






 
Ref. Ares(2022)3545646 - 10/05/2022
EUROPEAN COMMISSION 
Cabinet of Executive Vice-President Valdis Dombrovskis 
Brussels, 
2021 
Virtual Meeting with EFPIA 
26/11/2021
----- 
MINUTES 
Minutes of the meeting: 
On Friday 26 November, 2021, Executive Vice President Valdis Dombrovskis met with the 
European Federation of Pharmaceutical Industries and Associations (EFPIA) and some of 
their members, at their proposal. 
The meeting was requested to discuss the health initiatives under discussion at the WTO, the 
bilateral trade negotiations (e.g. with New Zealand), as well as other sectoral strategies of the 
European Commission and their possible effect on the international aspects of the European 
pharmaceutical industry. All initiatives of direct concern for EFPIA and their member 
companies and they argue to an alignment of the EU’s internal and external strategies.  EFPIA 
outlined the importance of the pharmaceuticals sector for the EU economy and health. The 
Commission noted the concerns of EFPIA and shared the current state of the negotiations. 
Topics: WTO and bilateral trade related issues 
TRN:  
EFPIA - 38526121292-88 
Bayer - 3523776801-85 
Sanofi - 61291462764-77 
Invitation:  
Briefing on: Basis (CAB DOMBROVSKIS/1293) 
Participants from the European Commission 
European Commission 
    Executive Vice President Mr. Valdis Dombrovskis 
Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111 

EFPIA and its members 
Art. 4.1 (b)

 EFPIA 
,
Art. 4.1 (b)
 Bayer Pharmaceuticals 
Art. 4.1 (b)
, General Medicines, Sanofi 
Art. 4.1 (b)
 EFPIA 
Art. 4.1 (b)
 EFPIA 
Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111